Podcasts about cpip

Les « Cold cases », que l'on traduit littéralement et brutalement par « affaires froides », désignent les affaires judiciaires non élucidées, c'est-à-dire celles pour lesquelles aucune explication n'a pu être donnée. L'affaire n'est pas résolue, le ou les coupable(s) n'ont pas été trouvés. Ces affaires font alors en principe l'objet d'un classement sans suite. Mais le classement sans suite n'est pas un jugement, ce n'est donc pas définitif. Il n'a pas autorité de la chose jugée, c'est-à-dire que cette décision de classement sans suite peut être remise en cause. Le Procureur de la République peut mettre fin au classement sans suite, c'est le cas par exemple si de nouveaux éléments sont trouvés ou que l'auteur peut être identifié. Une limite tout de même demeure : la prescription, même si elle peut être interrompue. On n'évoquera pas aujourd'hui les séries télé, bien que nos auditeurs fidèles savent que nous aimons en parler. Je pense notamment à la série américaine « Cold Case, affaires classées », retraçant le quotidien d'une inspectrice de police, Lilly Rush, chargée d'enquêter sur d'anciens dossiers classés sans suite. Une série toujours bien construite et une inspectrice Lilly Rush jouée par une actrice au charme indéniable mais je disgresse puisque j'ai dit que nous n'en parlerons pas. Dans ce podcast nous allons davantage évoquer le pôle des crimes sériels ou non élucidés du tribunal judiciaire de Nanterre, créé en mars 2022. C'est Charlotte Lepaisant, CPIP au SPIP de Paris, qui nous rejoint pour en parler.

Nous avons aujourd'hui le plaisir d'accueillir Charlotte LEPAISANT. Vous êtes titulaire d'un master 2 contentieux privé, obtenu en Normandie, à Caen, vous avez ensuite été assistante de justice en juridiction, juriste assistante en cabinet d'avocat, chroniqueuse justice chez ouest France, directrice d'un SPIP en milieu ouvert (contractuelle) dans le Calvados, pour présenter et réussir le concours de CPIP en 2017. En tant que CPIP, vous avez travaillé 2 ans dans l'Orne, milieu ouvert et fermé et notamment au sein de l'établissement sécuritaire de condé sur Sarthe. Et aujourd'hui vous êtes au SPIP MILIEU OUVERT de PARIS depuis septembre 2021. Si nous vous accueillons aujourd'hui dans les podcasts de l'ISP, Charlotte LEPAISANT, c'est pour parler du film sorti le 29 mars dernier dans les salles en France. C'est un réel succès : on a pu comptabiliser près de 500 000 spectateurs quinze jours après sa sortie. C'est une réussite pour la réalisatrice, Jeanne Herry qui a réussi à transpercer les spectateurs d'un sujet encore peu connu en France, à savoir la justice restaurative. Encore un sujet faisant société, tout comme son premier film, Pupille, sorti en le 26 août 2018. Pour la réalisation de son film, elle s'est entourée d'un casting qui parle de lui-même : Adèle Exarchopoulos, Dali Benssalah, Leïla Bekhti, Miou-Miou, Elodie Bouchez, Gilles Lellouche, Birane Ba, Fred Testot, Suliane Brahim et bien d'autres. Afin d'être au plus proche de la vérité, Jeanne Herry s'est inspirée de professionnels de terrain. Elle a travaillé avec l'Institut Français de la Justice Restaurative, des associations de victimes et des agents du SPIP. Ce film est poignant et traite d'un sujet dont on parle de plus en plus dans la justice française : la justice restaurative, Une notion, un concept consacré dans la loi du 15 août 2014 et mis en place par la circulaire du 15 mars 2017. Le film apporte un éclairage sur le fonctionnement et le déploiement pratique de la justice restaurative mais met également en lumière le métier de conseiller pénitentiaire d'insertion et de probation.

Distinguishing between type 1 and type 2 diabetes is critical, because delayed diagnosis of type 1 diabetes is associated with 20% or more risk of diabetic ketoacidosis, a major cause of death in children. Differentiating between type 1 and type 2 diabetes is also extremely important for choice of appropriate therapy. While the clinical presentation of a patient may not allow an unambiguous discrimination between type 1 and type 2 diabetes, the presence of one or more islet autoantibodies can support the diagnosis of type 1 diabetes, according to William Winter, MD, FCAP, the director of the UF Health Pathology Laboratories' Endocrinology Unit. Because islet autoantibodies can also predict the development of type 1 diabetes, once safe and effective therapies are available to prevent this disease, islet autoantibody testing will become routine in medical practice, as Dr. Winter explains in this CAPcast. Dr. Winter led the development of a Clinical Pathology Improvement Program or CPIP course on this topic.

In this episode of The Science of Selling STEM, I'll be sitting down with Jennifer Lauria Clark, CPIP. Jennifer is the Vice-President of Sales and Account Relationship Management for CAI, where she is responsible for business development project engineering, commissioning and qualification planning, protocol development and execution, project startup, and coordination, among other duties. She has 18 years of experience in the regulated industry. She held positions as a consultant, where she provided services for MERCK, GSK, Biogen, and others. Previously, she held positions at Yonkers Industries where she provided services for Merck, BD, GSK, Biogen, and others. Jennifer Lauria Clark has been a Member of ISPE for more than 19 years and is actively involved in the Society's local and international activities. She is the Past President of the ISPE CaSA Chapter, is a member and Past Chair of ISPE's Emerging Leaders Committee, and is a past member of ISPE's Pharmaceutical Engineering Committee. Currently, Jennifer Lauria Clark is the Chair of the International Women in Pharma team and is the chair of the 2020 Annual Meeting Planning Committee. She has a degree in Industrial Engineering from North Carolina State University and earned her CPIP designation in 2012. She is also currently working on her MBA from NC State Jenkins School of Management. Jennifer is passionate about people and enjoys spending time getting to know individuals and helping solve their problems. Tune in as she shares her experience and wisdom as a woman in sales who leads an entire sales organization, and keeps killing it year in year. On Today's Episode of the Science of Selling STEM: Her indoctrination into the pharmaceutical/biotech industry from a young age (01:52) The journey from individual contributor to vice-president of sales (04:23) How the dynamic of two women running the sales organization in a very technical company was like (06:42) Why women in sales should soften the approach by standing their ground (08:25) Applying active listening and empathy in collaborating with clients to create the best solutions for them (13:15) Moments that had her doubting whether she wanted to be in sales (15:09) Making sure you take some time out for yourself so you can perform better (18:00) Learning how to work smarter not harder, and how powerful it's been (19:52) Implementing a new employee orientation to better sell solutions to clients (24:00) Taking pride in helping create a marketing and sales organization in a company that didn't think they needed it (26:27) Achieving great success in sales from being genuine (29:01) Connect with Jennifer Clark: https://www.linkedin.com/in/jenniferlauriaclark/ (Jennifer on LinkedIn) Connect with Wesleyne Greer: https://transformedsales.com/ (Wesleyne's Website) https://www.linkedin.com/in/wesleynegreer/ (Wesleyne on LinkedIn) https://web.facebook.com/wesleynegreer (Wesleyne on Facebook) https://twitter.com/wesleynegreer (Wesleyne on Twitter) Rate, Review, Learn, and Share Thanks for tuning into The Science of Selling STEM! If you enjoyed this episode and want to learn even more about what it takes to transform your sales, don't forget to tune into our other episodes and share your favorite episodes on social media! Join The Science of Selling STEM community onhttps://www.facebook.com/WesleyneGreerCEO ( Facebook), https://twitter.com/WesleyneGreer (Twitter),https://www.linkedin.com/in/wesleynegreer/ ( LinkedIn) and https://www.transformedsales.com/ (visit my website) for even more content, information, and resources.

Welcome back listeners! In this episode #ThePaedipodsCast host, Mr Pranai Buddhdev, sits with Mr Mark Gaston from Sick Kids in Edinburgh. We discuss what it is like to be in the new hospital, his training & fellowship experience in Basel, Switzerland before diving into all things cerebral palsy. We talk about how they set up the Cerebral Palsy Integrated Pathway (Scotland) Service, and its outcomes in reducing surgery and improving management in patients with hip subluxation in CP. We talk about new research and the uses of the adoption of CPIP by NHS England. Visit cpipuk.org to learn about the 1st CPIP Meeting on 18th June 2021!!

Absolute Eosinophilia: A Practical Approach is the latest activity from the CAP’s Clinical Pathology Improvement Program, also known as CPIP (https://capatholo.gy/3aIYr4K). This activity describes a pragmatic approach for the workup of eosinophilia, including the appropriate application of molecular genetic studies, explains on of the CPIP case authors, Vandita Johari, MD, FCAP, in this CAPcast interview.

Today's guest is Professor Adam Mossoff, a leading scholar of intellectual property and Co-Founder of Scalia Law's Center for the Protection of Intellectual Property (CPIP). Three years ago, CPIP and the Gray Center co-hosted a major conference on the Patent Trial and Appeal Board (PTAB), a new regulatory body empowered to revoke companies' patents through an administrative process instead of a... Source

Today’s guest is Professor Adam Mossoff, a leading scholar of intellectual property and Co-Founder of Scalia Law’s Center for the Protection of Intellectual Property (CPIP). Three years ago, CPIP and the Gray Center co-hosted a major conference on the Patent Trial and Appeal Board (PTAB), a new regulatory body empowered to revoke companies’ patents through an […]Join the conversation and comment on this podcast episode: https://ricochet.com/podcast/arbitrary-capricious/adam-mossoff-on-the-innovation-economy-and-the-administrative-state/.Now become a Ricochet member for only $5.00 a month! Join and see what you’ve been missing: https://ricochet.com/membership/.Subscribe to Arbitrary & Capricious in Apple Podcasts (and leave a 5-star review, please!), or by RSS feed. For all our podcasts in one place, subscribe to the Ricochet Audio Network Superfeed in Apple Podcasts or by RSS feed.

Patients with cirrhosis are frequently transfused with platelets and plasma, yet the optimal role of these blood products may be poorly understood by ordering providers. It is important for pathologists to evaluate the available evidence supporting or refuting the use of these blood products in this population and be able to have conversations with gastroenterology colleagues about optimizing the transfusion plans for their mutual patients, explains Dr. Alexis Peedin in this CAPcast interview. Dr. Peedin led the development of a Clinical Pathology Improvement Program—also known as CPIP—on this topic (https://capatholo.gy/3hIpY7g).

Patients treated with opioids for noncancer chronic pain are known to exhibit aberrant drug behaviors. The urine drug screen or UDS complements behavior monitoring as an objective means to assess patient compliance. UDS results can impact decisions related to a patient’s treatment, including discontinuation of opioid therapy or removal of the patient from the treatment program, explains Barbarajean Magnani, MD, PhD, FCAP, in this CAPcast interview. Dr. Magnani, a renowned expert in toxicology, helped developed a Clinical Pathology Improvement Program or CPIP course on this topic (https://capatholo.gy/3cz90XA).

While many hospitals don’t frequently activate massive transfusion protocols (or MTPs), these events may be stressful and confusing for laboratory personnel. And because of the low frequency of MTP activation without designated trauma centers, there may be confusion as to the appropriate laboratory protocol, explains Dr. Alexis Peedin in this CAPcast. Dr. Peedin helped lead the development of a Clinical Laboratory Improvement Program (or CPIP) course on this topic: https://capatholo.gy/2LfNkDI.

The laboratory and pathologist play an essential role in the diagnosis of hemophagocytic lymphohistiocytosis or HLH. The pathologist’s morphologic diagnosis as well as direction to appropriate additional testing are truly essential for patient care, explains Dr. Megan Nakashima in this CAPcast. Dr. Nakashima also helped developed a course on this topic as part of the CAP’s Clinical Laboratory Improvement Program, or CPIP: https://capatholo.gy/31JGonR.

Protein electrophoresis is commonly ordered for patients with suspected or known plasma cell disorders. Pathologists may sometimes be unsure of the sequence in which tests should be ordered when evaluating for a plasma cell neoplasm, and it’s important to understand the utility and the limitations of each test, and its unique role in arriving at an accurate conclusion. In this CAPcast, Dr. Diana Desai provides an overview of protein electrophoresis and some challenges that pathologists should be aware of when ordering these tests. Dr. Desai developed a course on this topic as part of the CAP’s Clinical Laboratory Improvement Program, or CPIP (https://capatholo.gy/32LNx80).

Acute promyelocytic leukemia (APL) with PML-RARA is a true clinical emergency. Due to the rapid onset of this disease and rapid deterioration of the patient, it is important for pathologists to quickly and accurately identify APL, explains Dr. Juli-Anne Gardner in this CAPcast. Dr. Gardner developed a Clinicial Pathology Improvement Program or CPIP course on this topic (https://capatholo.gy/2Zw1tku).

MAHA is a nonimmune condition characterized by hemolytic anemia either due to abnormalities in the microvasculature or to intravascular devices that lead to fragmentation of the red blood cells. When MAHA is combined with thrombocytopenia, it is referred to as thrombotic microangiopathy (TMA). Pathologists may get requisitions for peripheral blood smear review that say “rule out MAHA”, explains hematopathologist Dr. Vandita Johari. While these may appear like a simple question, these patients tend to be complex and have multiple comorbid conditions and a clear understanding of the laboratory findings and approach to differential diagnosis of this condition is required to provide an appropriate answer. Dr. Johari lead the development of a case-based course on this topic as part of the CAP’s Clinical Pathology Improvement Program—or CPIP (https://capatholo.gy/2zdW1rR).

Statistical quality control or QC is a fundamental part of clinical laboratory practice; it assures that methods are performing at their usual level. Laboratories can make two main types of errors in selecting QC rules: too tight or too loose and both have ramifications, explains CAP inspector Dr. Robert Dufour in this CAPcast. If control limits are set too tight, time and money will be spent evaluating results that are already acceptable for patient care needs. However, use of too loose control limits will prevent them from detecting changes in method performance that may lead to suboptimal patient care and PT failures, explains Dr. Dufour, who also led the development of a CME course (https://capatholo.gy/2YXzY2M) on this topic as part of the CAP’s Clinical Laboratory Improvement Program or CPIP.

Highly sensitive next-generation sequencing-based assays have driven a rapid expansion of gene-disease associations for a diverse group of segmental overgrowth syndromes. In this CAPcast, Dr. Jonathan Heusel, a pathologist at the Washington University School of Medicine in St. Louis, discusses the medical director’s role in selecting both the appropriate assays and the reference laboratories to ensure high diagnostic yield. Dr. Heusel lead the development of a case-based course on this topic as part of the CAP’s Clinical Pathology Improvement Program—or CPIP: https://capatholo.gy/2xGJxbd.

Supporting the platelet transfusion needs of refractory patients is very resource intensive. These patients present numerous challenges for all clinical providers, including pathologists, because they typically have multiple comorbidities, are receiving multiple medications, and given the low platelet count, are at risk for bleeding. Because of the suboptimal response to platelets, these patients typically receive more transfusions compared to non-refractory patients, according to Dr. Monica Pagano, Medical Director of the Transfusion Service Laboratory at UW Medical Center in Seattle, in this CAPcast. Dr. Pagano lead the development of a case-based course on this topic as part of the CAP’s Clinical Pathology Improvement Program—or CPIP (https://capatholo.gy/2X6gb0b).

With special guest Adrienne Commeree, CPC, CPMA, CCS, CEMC, CPIP, a regulatory specialist for the HCPro Certified Coder Boot Camp® programs. She is an instructor with extensive knowledge of inpatient coding guidelines as well as E/M and auditing guidelines. Co-hosted by Laurie Prescott, MSN, RN, CCDS, CCDS-O, CDIP, CRC, the CDI education director for ACDIS in Middleton, Massachusetts. To read Physicians often unsure of diagnoses, underestimate error rate from Medscape.com as featured on In the News, please click here.

Discussion centers on the uncertainty in the United States patent system and the the “de-propertization” of intellectual property and those organizations that are driving a negative false narrative that patent trolls are ruining the system and the US needs to legislate a new solution. Adam Mossoff Adam Mossoff is Professor of Law at Antonin Scalia Law School, George Mason University. He is a founder of the Center for the Protection of Intellectual Property, and is now a Director of Academic Programs and a Senior Scholar. He teaches a wide range of courses at the law school, including property, patent law, trade secrets, trademark law, remedies, and internet law. He has published extensively on the theory and history of how patents and other intellectual property rights are fundamental property rights that should be secured to their owners and legally protected as commercial assets in the marketplace. He has testified before the Senate and the House on patent legislation, and he has spoken at numerous congressional staff briefings and academic conferences, as well as at the PTO, the FTC, the DOJ, the National Academy of Sciences, and the Smithsonian Museum of American History. His writings on patent law and policy have also appeared in the New York Times, Forbes, Investors Business Daily, The Hill, Politico, and in other media outlets. He is a member of the Public Policy Committee of the Licensing Executives Society, an appointed member of the Amicus Committee of the American Intellectual Property Law Association, and a member of the Academic Advisory Committee of the Copyright Alliance. He has served as past Chair and Vice-Chair of the Intellectual Property Committee of the IEEE-USA.

  IP Frequently – where, while always fair, nothing is off limits. We invite you to join the conversation. Discussion centers on the uncertainty in the United States patent system and the the “de-propertization” of intellectual property and those organizations that are driving a negative false narrative that patent trolls are ruining the system and […]

On May 30, 2017, the Supreme Court decided Impression Products, Inc. v. Lexmark International, Inc. Lexmark International, Inc. (Lexmark), which owns many patents for its printer toner cartridges, allows customers to buy its cartridges through a “Return Program,” which is administered under a combination single-use patent and contract license. Customers purchasing cartridges through the Return Program are given a discount in exchange for agreeing to use each cartridge once before returning it to Lexmark. All of the domestically-sold cartridges at issue here and some of those sold abroad were subject to the Return Program. Impression Products, Inc. (Impression) acquired some Lexmark cartridges abroad--after a third party physically changed the cartridges to enable their re-use--in order to resell them in the United States. Lexmark then sued, alleging that Impression had infringed on Lexmark’s patents because Impression acted without authorization from Lexmark to resell and reuse the cartridges. Impression contended that its resale of the cartridges was not an infringement because Lexmark, in transferring the title by selling the cartridges initially, granted the requisite authority. The district court granted Impression’s motion to dismiss as it related to the domestically sold cartridges but denied it as to the foreign-sold cartridges. The U.S. Court of Appeals for the Federal Circuit reversed the district court’s judgment as to the domestically sold cartridges but affirmed dismissal regarding the cartridges sold abroad. -- There were two questions before the Supreme Court: (1) whether a “conditional sale” that transfers title to the patented item while specifying post-sale restrictions on the article's use or resale avoids application of the patent-exhaustion doctrine and therefore permits the enforcement of such post-sale restrictions through the patent law’s infringement remedy; and (2) whether, in light of this court’s holding in Kirtsaeng v. John Wiley & Sons, Inc. that the common-law doctrine barring restraints on alienation that is the basis of exhaustion doctrine “makes no geographical distinctions,” a sale of a patented article – authorized by the U.S. patentee – that takes place outside the United States exhausts the U.S. patent rights in that article. -- By a vote of 7-1, the Supreme Court reversed the judgment of the Federal Circuit and remanded the case. In an opinion by Chief Justice Roberts, the Court held that (1) Lexmark exhausted its patent rights in toner cartridges sold in the United States through its "Return Program"; and (2) Lexmark cannot sue Impression Products for patent infringement with respect to cartridges Lexmark sold abroad, which Impression Products acquired from purchasers and imported into the United States, because an authorized sale outside the United States, just as one within the United States, exhausts all rights under the Patent Act. The Chief Justice’s majority opinion was joined by Justices Kennedy, Thomas, Breyer, Alito, Sotomayor, and Kagan. Justice Ginsburg filed an opinion concurring in part and dissenting in part. Justice Gorsuch took no part in the consideration or decision of the case. -- And now, to discuss the case, we have Adam Mossoff, who is Professor of Law and Co-Director of Academic Programs and Senior Scholar of CPIP, Antonin Scalia Law School, George Mason University.

Last Wednesday the Supreme Court handed down a 6-2 opinion resolving a long mystifying test of when a feature of a useful article may be protected by copyright law. Hewing closely to the text of the Copyright Act, the opinion, authored by Justice Thomas, announced a new separability test holding that a feature incorporated into the design of a useful article is eligible for copyright protection if the feature (1) can be perceived as a 2 or 3 dimensional work of art separate from the useful article and (2) would qualify as a protectable pictorial, graphic, or sculptural work if it were imagined separately from the useful article. -- Professor Sandra Aistars of Antonin Scalia Law School at George Mason University explored the implications for copyright in general and industries beyond fashion. -- Featuring: Prof. Sandra Aistars, Clinical Professor and Senior Scholar and Director of Copyright Research and Policy of CPIP, Antonin Scalia Law School, George Mason University.

On October 6, 2016, the Federal Trade Commission released the long-awaited results of its 6(b) study on patent assertion entities (PAEs). The study provides detailed information about the litigation and licensing activities by the approximately twenty companies the FTC ordered to submit data. The study does more than just describe this data, though. Given that PAEs' function in the innovation industries, the FTC also proposed a number of legislative and judicial recommendations concerning how patents are asserted against alleged infringers. Thus, the FTC's PAE study is an important part of the policy debates about patents, patent licensing, patent litigation, and the impact these have on the innovation economy. In this Teleforum, the panelists discussed the study findings and their reactions to the study and its policy proposals. -- Featuring: Prof. Jorge L. Contreras, Associate Professor, S.J. Quinney College of Law, University of Utah; Prof. Kristen Osenga, Professor of Law, University of Richmond School of Law; and Ms. Laurie Self, Vice President and Counsel of Government Affairs, Qualcomm Incorporated. Moderator: Prof. Adam Mossoff, Professor of Law and Co-Director of Academic Programs and Senior Scholar of CPIP, Antonin Scalia Law School, George Mason University.

Heres your 12th episode of the cpcast. Its short but packed. So we begin with the news about the medival party and we review and tell the secrets for three new catalogs! Were extending the listener art contest a few weeks so start making submissions. Lots of rumors about CPIP and of course theres the polls and listener feedbacks and we close out the show with some music and bloopers. Remember our email is clubpenguinpodcast@gmail.com and our site is clubpenguinpodcast.com. Support the show by clicking on our sponser's ads on the site!